A Phase 1/2a, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity
Latest Information Update: 29 Oct 2026
At a glance
- Drugs WVE 007 (Primary)
- Indications Obesity; Overweight
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms INLIGHT
- Sponsors WaVe life Sciences
Most Recent Events
- 27 Oct 2026 According to a Wave Life Sciences media release, The company plans to share data from the Phase 1 600 mg SAD cohort in the fourth quarter of 2026.
- 27 Oct 2026 According to a Wave Life Sciences media release, The Phase 2a portion of this trial is evaluating participants with greater adiposity and enrolling participants across the U.S. and Europe.
- 26 Oct 2026 The protocol has been amended to addition in treatment arms.